Allogene Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLO research report →
About the company
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
- CEO
- Zachary Roberts
- IPO
- 2018
- Employees
- 152
- HQ
- South San Francisco, CA, US
Price Chart
Get TickerSpark's AI analysis on ALLO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $431.65M
- P/E
- -2.30
- P/S
- 0.00
- P/B
- 1.53
- EV/EBITDA
- -3.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.45%
- ROIC
- -50.58%
- Revenue
- $0 · -100.00%
- Net Income
- $-190,886,000 · 25.90%
- EPS
- $-0.87 · 34.09%
- Op Income
- $-206,933,000
- FCF YoY
- 25.55%
- 52W High
- $4.46
- 52W Low
- $0.98
- 50D MA
- $2.04
- 200D MA
- $1.84
- Beta
- 0.46
- Avg Volume
- 8.29M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Roberts Zachary | other | 476,190 |
| Jul 1, 26 | Roberts Zachary | other | 134,530 |
| Jun 18, 26 | Kazam Joshua A | other | 47,700 |
| Jun 18, 26 | Kazam Joshua A | other | 95,400 |
| Jun 18, 26 | Kazam Joshua A | other | 47,700 |
| Jun 18, 26 | MESSEMER DEBORAH M. | other | 95,400 |
| Jun 18, 26 | Mayo Stephen | other | 144,400 |
| Jun 18, 26 | SATO VICKI L | other | 95,400 |
| Jun 18, 26 | WITTE OWEN N. | other | 95,400 |
| Jun 18, 26 | Humer Franz B | other | 95,400 |
Our ALLO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ALLO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
globenewswire.com · Jul 15
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
seekingalpha.com · Jul 4
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
zacks.com · Jun 12
Allogene Therapeutics Announces Planned CEO Succession
globenewswire.com · May 28
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com · May 26
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
zacks.com · May 14
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
247wallst.com · May 14
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is ALLO a buy or a sell from here?